Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research SessionMarlborough, Massachusetts--(Newsfile ...

faster timelines, and increased patient populations. In particular, global clinical trials can potentially lead to simultaneous launches of new medical products in multiple regions across the ...

Gov. Kathy Hochul is backing a push by prosecutors to revise discovery laws that were passed alongside bail reform in 2019.

Submission for New Intended Use That Leverages Company’s Patented OneRF® Technology Platform Expected in May 2025 EDEN PRAIRIE, Minn., March 11, ...

Ocugen has scheduled a conference call and webcast for 8:30 a.m. ET today to discuss the financial results and recent business highlights. Ocugen’s leadership team will host the call, which will be ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the approval and ...

The EU clinical trials law is currently up for revision ... via EU portal • Risk-based assessment approach • Clear timelines with tacit approval mechanisms (if authorities have not reacted ...

Senator Chuck Schumer of New York, the Democratic leader, broke with his party on Thursday and said he would vote for a ...

The U.S. Supreme Court dealt a blow to President Donald Trump's foreign-aid freeze, reinstating a lower court order that ...

Q4 2024 Earnings Call Transcript March 5, 2025 Ocugen, Inc. reports earnings inline with expectations. Reported EPS is $-0.05 ...

Agenus has robust end-to-end development capabilities, across commercial and clinical ... laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory ...

Ocugen (NASDAQ: OCGN) Q4 2024 Earnings Call Mar 05, 2025, 8:30 a.m. ET ...